High-throughput screening for drug discovery targeting the cancer cell-microenvironment interactions in hematological cancers

Abstract

Introduction:The interactions between leukemic blasts and cells within the bone marrow environment affect oncogenesis, cancer stem cell survival, as well as drug resistance in hematological cancers. The importance of this interaction is increasingly being recognized as a potentially important target for future drug discoveries and developments. Recent innovations in the high throughput drug screening related technologies, novel ex-vivo disease-models, and freely available machine-learning algorithms are advancing the drug discovery process by targeting earlier undruggable proteins, complex pathways, as well as physical interactions (e.g., leukemic cell-bone microenvironment interaction). Area covered:In this review, the authors discuss the recent methodological advancements and existing challenges to target specialized hematopoietic niches within the bone marrow during

SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples

“…Historically, drug combinations have been identified using a trial-and-error method that requires considerable time and may lead to sub-optimal results ( 7 , 11 , 12 ). High-throughput screening (HTS) technologies have enabled a more systematic and accelerated discovery of new drug combination candidates ( 4 , 9 , 13–15 ). With HTS, thousands of drugs combinations can be tested in multiple doses in preclinical model systems to identify synergistic drug combinations, i.e.…”

From Myricetin to the Discovery of Novel Natural Human ENPP1 Inhibitors: A Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and MM/GBSA Study

“…HTS has become a routine drug discovery process for the identification of novel hit compounds against interesting targets. This process can screen huge chemical libraries rapidly to find the most promising compounds [ 33 , 34 ]. However, it also requires considerable cost and time.…”

The Art of Finding the Right Drug Target: Emerging Methods and Strategies

“…In the future, to truly address these multifaceted challenges, an integrated approach must be adopted that fully combines traditional experiments, highthroughput techniques, computational modelling, and artificial intelligence (Nayarisseri 2020;Giri and Ianevski 2022;Rifaioglu et al, 2019;You et al, 2022) to improve the accuracy and efficiency of target discovery and verification. Furthermore, as technology evolves, drug target discovery methods are expected to become more sophisticated, more efficient, and impactful, transforming drug development, driving innovation, and paving the way for developing more effective targeted therapies for human diseases.…”